Author

Aparna Krishnan

Columbia University Irving Medical CenterPrimary ORCID profile (0000-0001-9781-1157 · 2 papers)Unclaimed ORCID profile · follow to get notified of new preprints

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Same name, identified by ORCID

Aparna KrishnaniD2 papers · Tata Institute of Fundamental Research

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Approach:experimental assay· 1 Research Focus:host-pathogen & immune response· 1 Organism:mouse· 1

Frequent Co-Authors

Anil Rustgi· 1 shared Anna M. ChiarellaiD· 1 shared Benjamin IzariD· 1 shared Bret TabackiD· 1 shared Brian E. Ragaishis· 1 shared Catherine S. SpinaiD· 1 shared Chang Liu· 1 shared Chelsea L. Rahiman· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Anil Rustgi

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Targeting CD73-A2aR-Mediated Adenosine Signaling at the Tumor-Immune Interface Overcomes Radioresistance

Shruti Bansal, Luis Aparicio, Aparna Krishnan, Chang Liu, Lindsay Caprio, Anna M. Chiarella, Samanta Sarti, Jason Piersant, Chelsea L. Rahiman, Julia An, Patrick McCann, Namita Sen, Brian E. Ragaishis, Fatemeh N. Derakhshan, Bret Taback, , Catherine S. Spina

This study shows that targeting CD73-A2aR adenosine signaling with radiotherapy and checkpoint inhibitors improves tumor control by overcoming radioresistance and enhancing antitumor immunity.

bioRxiv · May 29, 2026 · PreprintCancer Biology